Logo-jnp
J Nephropathol. 2021;10(1): e05.
doi: 10.34172/jnp.2021.05
  Abstract View: 223
  PDF Download: 101

Original Article

Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics

Ali Nosrati Andevari 1,2 ORCID logo, Soheila Moein 1,2 * ORCID logo, Durdi Qujeq 3,4 * ORCID logo, Zoleikha Moazezi 5 ORCID logo, Karimollah Hajian Tilaki 6 ORCID logo

1 Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 Department of Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
5 Department of Internal Medicine, School of Medicine, Babol University of Medical Sciences, Babol, Iran
6 Department of Statistics and Epidmiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
*Corresponding author: 1. Soheila Moein, Email;soheila_9@yahoo.com, smoein@hums.ac.ir; 2. Durdi Qujeq, Email;dqujeq@gmail.com and D.qujeq@mbabol.ac.ir soheila_9@yahoo.com

Abstract

Introduction: Atorvastatin hinders cardiovascular disease by reducing cholesterol levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) enhances the secretion of insulin by binding to LDL receptor. Sortilin is committed in the transfer of intracellular proteins through the plasma membrane.

Objectives: The purpose of this research was to determine the effect of atorvastatin consumption on alterations in the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA-R), PCSK9 and sortilin in diabetic patients and pre-diabetics.

Patients and Methods: This study was carried out on 80 individuals including normal subjects, diabetic patients and pre-diabetics. The participated individuals were divided as control group (i) (healthy individuals without diabetes mellitus), diabetic group receiving statin (ii), diabetic group not receiving statin (iii), pre-diabetic group receiving statin (iv) and pre-diabetic group not receiving statin (v). Levels of HMG-COA-R, PCSK9 and sortilin were determined by ELISA method.

Results: In diabetics and pre-diabetics taking atorvastatin, the level of HMG-COA-R was not altered significantly compared to diabetics and pre-diabetics not taking atorvastatin, respectively (P> 0.05). The serum PCSK9 level in diabetics and pre-diabetics was significantly higher than the healthy individuals (P= 0.001). Additionally, the serum PCSK9 level in diabetics and pre-diabetics receiving atorvastatin was significantly higher than diabetics and pre-diabetics not receiving atorvastatin, respectively (P=0.001). The serum sortilin level in diabetics and pre-diabetics was significantly higher than the healthy individuals (P=0.001). In addition, the serum sortilin level in pre-diabetics receiving atorvastatin was significantly higher than pre-diabetics not receiving atorvastatin (P=0.001).

Conclusion: Atorvastatin improved insulin secretion and sensitivity by increasing serum sortilin and PCSK9 levels. Thereby, it prevented the development of diabetes in diabetics and the progression of pre-diabetes to diabetes in pre-diabetics.

Keywords: Diabetics, Pre-diabetics, HMG-COA-R, Sortilin, Atorvastatin, Insulin

Implication for health policy/practice/research/medical education:

In a clinical study on 80 individuals including normal subjects, diabetic patients and pre-diabetics, atorvastatin improved insulin secretion and sensitivity by increasing serum sortilin and PCSK9 levels.

Please cite this paper as: Nosrati Andevari A, Moein S, Qujeq D, Moazezi Z, Hajian Tilaki K. Effects of atrovastatin on concentrations of 3-hydroxy-3-methyl-glutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics. J Nephropathol. 2021;10(1):e05. DOI: 10.34172/jnp.2021.05.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 223

Your browser does not support the canvas element.


PDF Download: 101

Your browser does not support the canvas element.

Submitted: 13 Apr 2020
Accepted: 10 Jun 2020
ePublished: 02 Jul 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)